CELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis

CELLINK AB (publ) (“CELLINK”) has entered into an agreement with the shareholders of Ginolis Oy (“Ginolis”), a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the “Acquisition”). Forty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Extraordinary General Meeting held on December 17, 2020.

More News